Skip to main content
67°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cassava Sciences Inc
(NQ:
SAVA
)
30.95
+1.11 (+3.72%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cassava Sciences Inc
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD
December 20, 2022
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease
December 06, 2022
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Announces Closing of $50 Million Registered Direct Offering
November 22, 2022
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
November 18, 2022
From
Cassava Sciences, Inc.
Via
GlobeNewswire
CASSAVA SCIENCES INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA
November 11, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
November 07, 2022
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” Campaign
November 03, 2022
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Cassava Sciences Announces Expansion of Leadership Team
October 27, 2022
From
Cassava Sciences, Inc.
Via
GlobeNewswire
Alzheimer’s Pipeline of New Treatments Race to Improve Quality of Life for Patients
October 20, 2022
Palm Beach, FL – October 20, 2022 – FinancialNewsMedia.com News Commentary – Last year, about 6.2 million people aged 65 and above living in America were suffering from Alzheimer’s disease, (AD) which...
Via
FinancialNewsMedia
CASSAVA SCIENCES INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA
October 14, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Cassava Sciences Announces Initiation of an Open-label Extension Study
October 13, 2022
From
Cassava Sciences, Inc.
Via
GlobeNewswire
3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
October 06, 2022
Here is a look at three names that buy-and-hold investors may want to consider as the race to find a cure for Alzheimer's disease accelerates
Via
MarketBeat
Exposures
Product Safety
CASSAVA SCIENCES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Cassava Sciences, Inc. - SAVA
August 12, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Cassava Sciences Responds to Media Reports
July 27, 2022
From
Cassava Sciences, Inc.
Via
GlobeNewswire
CASSAVA SCIENCES INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Cassava Sciences, Inc. - SAVA
July 15, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions
June 29, 2022
Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the...
Via
FinancialNewsMedia
Cassava Sciences, Inc. (NASDAQ:SAVA) Investor Alert: Investigation over Possible Violations of Securities Laws
June 02, 2022
San Diego, CA -- (SBWIRE) -- 06/02/2022 -- Cassava Sciences, Inc is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
Global Psychedelics Market Is Expected To Reach $8 Billion By 2029
May 24, 2022
Palm Beach, FL – May 24, 2022 – FinancialNewsMedia.com News Commentary – The Global psychedelic drugs market has been steadily rising for the past few years and is projected to continue at a faster...
Via
FinancialNewsMedia
CASSAVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Cassava Sciences, Inc. on Behalf of Cassava Stockholders and Encourages Investors to Contact the Firm
April 21, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
R&D Efforts for Alzheimer’s Therapies on the Rise with over 120 Drugs in Development
March 31, 2022
Palm Beach, FL – March 31, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is an irreversible, progressive neurodegenerative disease. It is the most common cause of dementia...
Via
FinancialNewsMedia
Top Ideas in the Small Cap Biotech Space (LEXTF, ABBV, SAVA, SNDL, RETA, PAHC)
January 24, 2022
Via
AB Newswire
Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
January 19, 2022
Via
AB Newswire
Topics
Bonds
Stocks
Exposures
Debt Markets
US Equities
Global Alzheimer’s Disease Therapeutics Market Projected To Generate Revenue Of $9.97 Billion By 2028
January 04, 2022
Palm Beach, FL –January 4, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease is a degenerative, progressive ailment that attacks the brain’s nerve cells, resulting in memory loss,...
Via
FinancialNewsMedia
Exposures
COVID-19
CORRECTING and REPLACING CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
December 04, 2021
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
December 03, 2021
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Global Cancer Therapy Market Expected to Reach $268 Billion In 2026, With A CAGR Of 9.15%
November 16, 2021
Palm Beach, FL –November 16, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic has affected the healthcare systems globally and also has a significant impact on the cancer therapy...
Via
FinancialNewsMedia
Exposures
COVID-19
NASDAQ:SAVA Long Term Investor Notice: Investigation of Potential Wrongdoing at Cassava Sciences, Inc.
November 15, 2021
San Diego, CA -- (SBWIRE) -- 11/15/2021 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Cassava Sciences, Inc..
Via
SBWire
Topics
Lawsuit
Exposures
Financial
Legal
Artificial Intelligence Could Be About To Replace Your Doctor
November 02, 2021
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 2, 2021 – The US health and medical insurance industry is a $1.1-trillion maze that is impossible to navigate. And...
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
SHAREHOLDER ALERT: Robbins LLP Investigates Cassava Sciences, Inc. (SAVA) on Behalf of Shareholders
October 29, 2021
From
Robbins LLP
Via
Business Wire
SAVA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Cassava Sciences, Inc.
October 26, 2021
From
Glancy Prongay & Murray LLP
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.